Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer

Background Efatutazone, a novel oral highly-selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist, has demonstrated some inhibitory effects on disease stabilization in patients with metastatic colorectal cancer (mCRC) enrolled in previous phase I studies. Here, we evaluate the s...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Komatsu, Yoshito, Yoshino, Takayuki, Yamazaki, Kentaro, Yuki, Satoshi, Machida, Nozomu, Sasaki, Takahide, Hyodo, Ichinosuke, Yachi, Yutaka, Onuma, Hiroshi, Ohtsu, Atsushi
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer US 2013
נושאים:
Phase I Studies
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4045340/
https://ncbi.nlm.nih.gov/pubmed/24337768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0056-3
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים